Alliance Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Alliance Pharma has a total shareholder equity of £277.0M and total debt of £120.6M, which brings its debt-to-equity ratio to 43.6%. Its total assets and total liabilities are £513.7M and £236.8M respectively. Alliance Pharma's EBIT is £25.4M making its interest coverage ratio 3.2. It has cash and short-term investments of £26.1M.
Key information
43.6%
Debt to equity ratio
UK£120.64m
Debt
Interest coverage ratio | 3.2x |
Cash | UK£26.11m |
Equity | UK£276.96m |
Total liabilities | UK£236.76m |
Total assets | UK£513.72m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: DVL's short term assets (£94.7M) exceed its short term liabilities (£49.0M).
Long Term Liabilities: DVL's short term assets (£94.7M) do not cover its long term liabilities (£187.7M).
Debt to Equity History and Analysis
Debt Level: DVL's net debt to equity ratio (34.1%) is considered satisfactory.
Reducing Debt: DVL's debt to equity ratio has increased from 41.8% to 43.6% over the past 5 years.
Debt Coverage: DVL's debt is well covered by operating cash flow (24.1%).
Interest Coverage: DVL's interest payments on its debt are well covered by EBIT (3.2x coverage).